aiPTO is excited to be accepted into the prestigious NVIDIA Inception program, “designed to help startups accelerate innovation and growth. Program members get access to the latest developer resources and training, exclusive pricing on NVIDIA hardware and software, and exposure to the venture capital community”. We welcome NVIDIA’s support on the mission to revolutionize brain cancer therapy with next-generation patient avatar and deep generative AI. #NVIDIAInception #NVIDIA #AI #braincancer
AIPTO
Biotechnology Research
Revolutionize Brain Cancer Therapy with Patient Avatar & Artificial Intelligence
About us
AIPTO TechBio pioneers a groundbreaking patient avatar technology utilizing patient tumor explants and organoids to faithfully replicate in vivo tumor biology. Augmenting this innovation is a cutting-edge generative AI technology driven by unparalleled single-cell RNA sequencing data obtained from these patient avatars. By synergizing the power of patient avatars with advanced AI capabilities, AIPTO is positioned to revolutionize drug discovery and precision medicine for brain cancer patients, offering a transformative path towards improved treatment outcomes.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held